您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (6): 51-56.doi: 10.6040/j.issn.1671-7554.0.2021.1491

• • 上一篇    

前列腺特异性抗原同源异构体2及其衍生指标在前列腺癌诊断中的价值

许振,刁统祥,臧振杰,邵丁昌,张奇,孙鼎琪,傅强   

  • 发布日期:2022-06-17
  • 通讯作者: 傅强. E-mail:qiangfu68@163.com
  • 基金资助:
    山东省自然科学基金青年项目(ZR20211QH366)

Value of isoform［-2］proprostate-specific antigen and its derivatives in the diagnosis of prostate cancer

XU Zhen, DIAO Tongxiang, ZANG Zhenjie, SHAO Dingchang, ZHANG Qi, SUN Dingqi, FU Qiang   

  1. Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250021, Shandong, China
  • Published:2022-06-17

PDF (PC)

411

摘要： 目的 探讨前列腺特异性抗原同源异构体2(p2PSA)及其衍生指标前列腺健康指数(PHI)、前列腺健康指数密度(PHID)在前列腺癌诊断中的应用价值。 方法 收集2020年8月至2021年9月在山东大学附属省立医院行前列腺穿刺术的148例患者病例资料。根据穿刺病理结果将患者分为良性前列腺增生组(n=78)与前列腺癌组(n=70)。术前检测所有患者血清前列腺特异性抗原(PSA)、游离前列腺特异性抗原(fPSA)、p2PSA并计算出前列腺特异抗原密度(PSAD)、PHI和PHID。采用受试者工作特征(ROC)曲线评估各指标诊断前列腺癌的效能;术后病理进行Gleason评分,检测各项指标对高级别前列腺癌(Gleason评分≥7)的预测价值。 结果 与前列腺增生组比较,前列腺癌组PSA、PSAD、p2PSA、PHI、PHID均明显增高,差异均有统计学意义(P均<0.001)。ROC曲线分析结果显示,PSA、PSAD、p2PSA、PHI及PHID诊断前列腺癌的曲线下面积(AUC)分别为0.68、0.81、0.83、0.88、0.92。p2PSA、PHI及PHID诊断前列腺癌的价值优于PSA(P均<0.001);p2PSA、PHI、PHID诊断高级别前列腺癌的AUC分别为0.75、0.84、0.84,均高于PSA(AUC为0.69),差异均有统计学意义(P=0.026、P=0.009、P=0.028)。 结论 应用p2PSA、PHI、PHID可以提高前列腺癌诊断的特异性,更准确地预测高级别前列腺癌,对于评估肿瘤的恶性程度、生物学行为及预后有重要意义。

关键词: 前列腺癌, 前列腺特异抗原同源异构体, 前列腺健康指数, 前列腺健康指数密度, Gleason评分

Abstract: Objective To explore the value of isoform［-2］proprostate-specific antigen(p2psa), prostate health index(PHI)and prostate health index density(phid)in the diagnosis of prostate cancer. Methods Clinical data of 148 male patients who underwent prostate biopsy in our hospital during Aug. 2020 and Sep. 2021 were collected. According to the pathological results, the patients were divided into benign prostatic hyperplasia group(BPH, n=78)and prostate cancer group(PCa, n=70). Serum prostate specific antigen(PSA), free prostate specific antigen(fPSA)and p2PSA were determined before prostate biopsy, and prostate specific antigen density(PSAD), PHI and PHID were calculated. Receiver operating characteristic(ROC)curve was drawn to evaluate the efficacy of various indexes in the diagnosis of prostate cancer. The prostate pathological result was considered as the gold standard to evaluate the Gleason score of PCa patients and detect the value of various indexes in predicting high-grade PCa(Gleason score ≥7). Results Compared with BPH group, the PCa group had significantly higher PSA, PSAD, p2PSA, PHI and PHID(all P<0.001). ROC curve showed that the area under the curve(AUC)of PSA, PSAD, p2PSA, PHI and PHID in the diagnosis of PCa were 0.68, 0.81, 0.83, 0.88 and 0.92, respectively. The diagnostic value of p2PSA, PHI and PHID was better than that of PSA(all P<0.001). The AUC of p2PSA, PHI and PHID in the diagnosis of high-grade PCa were 0.75, 0.84 and 0.84, respectively, which were better than that of PSA(AUC=0.69)(P=0.026, P=0.009, P=0.028). Conclusion Detection of p2psa, PHI and PHID can improve the specificity of prostate cancer diagnosis and accurately predict high-grade prostate cancer. They are significant to evaluate the malignancy, biological behavior and prognosis of the tumor.

Key words: Prostate cancer, isoform［-2］proprostate-specific antigen, Prostate health index, Prostate health index density, Gleason score

中图分类号: 

  • R737.25
[1] Humphrey PA, Moch H, Cubilla AL, et al. The 2016 who classification of tumours of the urinary system and male genital organs-part b: prostate and bladder tumours [J]. Eur Urol, 2016, 70(1): 106-119.
[2] Fleshner K, Carlsson SV, Roobol MJ. The effect of the uspstf psa screening recommendation on prostate cancer incidence patterns in the UAS [J]. Nat Rev Urol, 2017, 14(1): 26-37.
[3] 刘冰, 罗志刚. [-2] proPSA及%p2PSA、PHI在前列腺癌诊断中的研究进展[J]. 中南医学科学杂志, 2017, 45(1): 105-108. LIU Bing, LUO Zhigang. Research progress of [-2] propsa,%p2psa and phi in the diagnosis of prostate cancer [J]. Medical Science Journal of Central South China, 2017, 45(1): 105-108.
[4] Al Saidi SS, Al Riyami NB, Al Marhoon MS, et al. Validity of prostate health index and percentage of -2 pro-prostate-specific antigen as novel biomarkers in the diagnosis of prostate cancer: omani tertiary hospitals experience [J]. Oman Med J, 2017, 32(4): 275-283.
[5] Ferro M, Cobelli O de, Lucarelli G, et al. Beyond psa: the role of prostate health index(phi)[J]. Int J Mol Sci, 2020, 2(4): 1184. doi: 10.3390/ijms21041184.
[6] Sriplakich S, Lojanapiwat B, Chongruksut W, et al. Prospective performance of the prostate health index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4-10 ng/mL and negative digital rectal examination [J]. Prostate Int, 2018, 6(4): 136-139.
[7] Chen R, Sjoberg DD, Huang Y, et al. Prostate specific antigen and prostate cancer in chinese men undergoing initial prostate biopsies compared with western cohorts [J]. J Urol, 2017, 197(1): 90-96.
[8] Liu Y, Xu Y. Serum p2PSA derivative indexes in prostate cancer: an update [J]. Zhonghua Nan Ke Xue, 2015, 21(1): 74-77.
[9] Ng CF, Chiu PKF, Lam NY, et al. The prostate health index in predicting initial prostate biopsy outcomes in asian men with prostate-specific antigen levels of 4-10 ng/mL [J]. Int Urol Nephrol, 2014, 46(4): 711-717.
[10] Hsieh PF, Chang CH, Yang CR, et al. Prostate health index(phi)improves prostate cancer detection at initial biopsy in taiwanese men with psa 4-10 ng/mL [J]. Kaohsiung J Med Sci, 2018, 34(8): 461-466.
[11] Fan YH, Pan PH, Cheng WM, et al. The prostate health index aids multi-parametric mri in diagnosing significant prostate cancer [J]. Sci Rep, 2021, 11(1): 1286. doi: 10.1038/s41598-020-78428-6.
[12] Loeb S, Sanda MG, Broyles DL, et al. The prostate health index selectively identifies clinically significant prostate cancer [J]. J Urol, 2015, 193(4): 1163-1169.
[13] Foj L, Filella X. Development and internal validation of a novel phi-nomogram to identify aggressive prostate cancer [J]. Clin Chim Acta, 2020, 501: 174-178. doi: 10.1016/j.cca.2019.
[14] Lazzeri M, Haese A, Abrate A, et al. Clinical performance of serum prostate-specific antigen isoform [-2] proPSA(p2PSA)and its derivatives, %p2PSA and the prostate health index(PHI), in men with a family history of prostate cancer: results from a multicentre European study, the Prometheus [J]. BJU Int, 2013, 112(3): 313-321.
[15] Chiu PKF, Roobol MJ, Teoh JY, et al. Prostate health index(PHI)and prostate-specific antigen(PSA)predictive models for prostate cancer in the Chinese population and the role of digital rectal examinationestimated prostate volume [J]. Int Urol Nephrol, 2016, 48(10): 1631-1637.
[16] Na R, Ye D, Liu F, Chen H,et al. Performance of serum prostate-specific antigen isoform [2] proPSA(p2PSA)and the prostate health index(PHI)in a Chinese hospital-based biopsy population [J]. Prostate, 2014, 74(15): 1569-1575.
[17] Tosoian JJ, Druskin SC, Andreas D, et al. Prostate health index density improves detection of clinically significant prostate cancer [J]. BJU Int, 2017, 120(6): 793-798.
[18] Garrido MM, Ribeiro RM, Pinheiro LC, Holdenrieder S, Guimarães JT. The prostate health index(phi)density: are there advantages over phi or over the prostate-specific antigen density? [J]. Clin Chim Acta, 2021, 520: 133-138. doi: 10.1016/j.cca.2021.06.006.
[19] Stephan C, Jung K, Lein M, et al. PHI density prospectively improves prostate cancer detection [J]. World J Urol, 2021, 39(9): 3273-3279.
[20] Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with her2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial [J]. Lancet Oncol, 2011, 12(3): 236-244.
[21] Dolejsova O, Kucera R, Fuchsova R, et al. The ability of prostate health index(phi)to predict gleason score in patients with prostate cancer and discriminate patients between gleason score 6 and gleason score higher than 6-a study on 320 patients after radical prostatectomy [J]. Technol Cancer Res Treat, 2018, 17: 1533033818787377. doi: 10.1177/1533033818787377.
[22] 黄宜, 王文涓, 许静, 等. p2PSA及其相关指标PHI在前列腺癌诊断中的应用价值[J]. 检验医学, 2019, 34(7): 600-604. HUANG Yi, WANG Wenjuan, XU Jing, et al. Role of p2psa and its related marker phi in the diagnosis of prostate cancer [J]. Laboratory Medicine, 2019, 34(7): 600-604.
[23] Stephan C, Vincendeau S, Houlgatte A, et al. Multicenter evaluation of -2proprostate-specific antigen and the prostate health index for detecting prostate cancer [J]. Clin Chem, 2013, 59(1): 306-314.
[24] Choi J, Kang M, Sung HH, et al. Correlation between Gleason score distribution and prostate health index in patients with prostate-specific antigen values of 2.5-10 ng/mL [J]. Investig Clin Urol, 2020, 61(6): 582-587.
[25] 孙奎霞, 闫存玲, 李志艳, 等. 前列腺特异性抗原同源异构体2及其衍生指标在预测前列腺癌病理分级中的价值[J]. 北京大学学报(医学版), 2020, 52(2): 234-239. SUN Kuixia, YAN Cunling, LI Zhiyan, et al. Clinical value of serum isoform _2 proprostate-specific antigen and its derivatives in predicting aggressive prostate cancer [J]. Journal of Peking University, 2020, 52(2): 234-239.
[1] 孙浩瑜,姜鑫,陈守臻,曲思凤,史本康. 多参数磁共振联合前列腺健康指数对PSA灰区临床有意义前列腺癌的诊断价值[J]. 山东大学学报 (医学版), 2022, 60(6): 46-50.
[2] 史本康,陈守臻,曲思凤,王勇,刘磊. 临床常见快速进展前列腺癌临床特点及研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 110-116.
[3] 徐兵,李勇,刘明,刘永辉. 沉默PRRX1基因表达可增强前列腺癌耐药细胞株PC-3/DTX对多西他赛的敏感性[J]. 山东大学学报 (医学版), 2021, 59(6): 103-110.
[4] 孙鼎琪,傅强,张辉,刘帅,刁统祥,曹庆伟,张克勤. 多参数磁共振与经直肠超声融合前列腺靶向穿刺活检在检测PI-RADS≥3前列腺癌中的临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 108-113.
[5] 翟红运, 张登禄, 王光杰, 孔峰, 程广辉, 赵升田. 小鼠胚胎干细胞分泌因子对前列腺癌细胞作用的体外研究[J]. 山东大学学报（医学版）, 2015, 53(9): 8-12.
[6] 丁焕1，孙颖1，黎晓晴2，黎莉1. PARP抑制剂联合吉西他滨或多西他赛对雄激素非依赖性前列腺癌PC3细胞增殖的影响[J]. 山东大学学报（医学版）, 2014, 52(1): 33-36.
[7] 高逢彬，司曼飞，刘永青，牛蕾蕾，苑辉卿. 网脊衣酸上调p21CIP1蛋白诱导前列腺癌细胞周期阻滞的作用分析[J]. 山东大学学报(医学版), 2013, 51(12): 34-40.
[8] 于张健1，张士宝1，刘庆勇1，阮喜云2，杨广笑3，王全颖3. SAC重组腺相关病毒载体的构建及其对前列腺癌CAM移植瘤的抑制作用[J]. 山东大学学报(医学版), 2012, 50(7): 41-.
[9] 许爱辉1，潘喆2，蒋汉明1，孔峰1，胡志敏3，苑辉卿1. 地前素M抗前列腺肿瘤活性的初步探讨[J]. 山东大学学报(医学版), 2010, 48(5): 18-22.
[10] 陈卫国1，龙慧民2，侯建全1，浦金贤1，严春寅1. Gefitinib对激素非依赖性前列腺癌的治疗及其效应初探[J]. 山东大学学报(医学版), 2010, 48(1): 52-55.
[11] 吉恺,孔峰,沈涛,王小玲,许爱辉,苑辉卿,张秀田 . 没药倍半萜成分的分离鉴定及抗肿瘤活性[J]. 山东大学学报(医学版), 2008, 46(4): 344-348.
[12] 王小玲,孔峰,许爱辉,吉恺,蔡捷,任凯,苑辉卿 . 没药倍半萜抑制前列腺癌细胞的增殖活性初探[J]. 山东大学学报(医学版), 2007, 45(12): 1189-1192.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发